Back to top
more

Affymax (AFFY)

(Delayed Data from OTC)

$0.00 USD

0.00
700

0.00 (0.00%)

Updated May 7, 2024 12:17 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (74 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AFFY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Affymax Inc. [AFFY]

Reports for Purchase

Showing records 21 - 40 ( 55 total )

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

05/07/2012

Daily Note

Pages: 3

Reports FY1Q12, While Investors Look for Insight into Launch

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

05/07/2012

Company Report

Pages: 7

Reports FY1Q12, While Investors Look for Insight into Launch

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 25.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

05/02/2012

Company Report

Pages: 5

A Reminder on Dialysis Margins: Read-Through from DaVita Earnings for AFFY

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

05/02/2012

Daily Note

Pages: 3

A Reminder on Dialysis Margins: Read-Through from DaVita Earnings for AFFY

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

04/25/2012

Daily Note

Pages: 3

Recap of Discussion with Senior AFFY Management on Omontys Commercialization Strategy

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

04/25/2012

Company Report

Pages: 4

Recap of Discussion with Senior AFFY Management on Omontys Commercialization Strategy

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

04/13/2012

Company Report

Pages: 4

Omontys Granted Q-Code from CMS Faster Than We Anticipated

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

04/13/2012

Daily Note

Pages: 3

Omontys Granted Q-Code from CMS Faster Than We Anticipated

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

03/28/2012

Company Report

Pages: 5

Right on Schedule, the FDA Approves Peginesatide

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

03/27/2012

Company Report

Pages: 7

Peginesatide Approved - Raising Target

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 25.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

03/27/2012

Daily Note

Pages: 3

Peginesatide Approved - Raising Target

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

03/23/2012

Company Report

Pages: 30

We are initiating coverage with a Market Outperform rating and a target price of $20.

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 75.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

03/23/2012

Daily Note

Pages: 3

We are initiating coverage with a Market Outperform rating and a target price of $20.

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

03/14/2012

Company Report

Pages: 5

4Q11 Results Review: Ramping Up for a Commercial Launch

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

03/12/2012

Company Report

Pages: 5

Raising Target to $17 ahead of Peginesatide March 27 PDUFA

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

12/16/2011

Company Report

Pages: 5

Change in Focus Leads Takeda Move Away from the Japanese Market; U.S. & EU on Track

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

12/08/2011

Company Report

Pages: 5

ODAC Votes 15-1-1 In Favor of Peginesatide; Sets the Stage for Full FDA Approval

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

12/06/2011

Company Report

Pages: 5

FDA Panel Documents Look Clean Ahead of Wednesday''s ODAC Review

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

12/02/2011

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Affymax Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

11/29/2011

Company Report

Pages: 5

Major Binary Event Looms Large

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party